Several study designs were identified, with clinical trials, observational studies, and post hoc analyses from clinical trials being the most common
Orforglipron 3 mg dose: 4.7% weight loss Orforglipron 12 mg dose: 6.1% weight loss Orforglipron 36 mg dose: 7.9% weight loss Placebo: 1.6% weight loss When bodyweight was compared between groups, orforglipron demonstrated a greater reduction than placebo and other GLP-1 receptor agonists in similar studies
Some people may lose weight right away, while others may see slower weight loss over weeks or months
Diabetes, 60 (9), 2308-14 PMID: 21868791 Holst JJ (2011)
GLP-1-based therapeutics have also been shown to lower the risk of neurodegenerative diseases and improve cardiovascular health, in addition to weight management and diabetes treatment 10
We found that the abundance of microorganisms and their corresponding metabolites in IBS-C and IBS-D differ, thereby providing a new avenue for the diagnosis and treatment of different IBS subtypes in the future